RLMD
Relmada TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
+
Peers tracked
11
U.S. public peers
Grade Position
Above peers
vs peer average
RLMD vs peer average
76/100
RLMD vs. peer average (A vs. C)
Grade spread
A 3 · B 3 · C 2 · D 1 · F 2
Graded peers loaded
Coverage
11 graded
100% of tracked
Peer overview
ALLO is the first available peer comparator.
Allogene is not indication-matched, yet it is a useful event-volatility comparator because investors similarly focus on trial progress, regulatory timing, and balance-sheet durability.
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
RLMD
Relmada Therapeutics
ALLO
Allogene Therapeutics
Grade
A
A
Momentum
90
96
Value
41
41
Sentiment
62
58
Setup Bias
Net Neutral
-
Market Cap
-
-
Posture
Constructive
Constructive
Grade position vs ALLO
RLMD / ALLO
Grade Position
Above peers
RLMD vs. peer average (A vs. C)
76/100
Momentum
90
ALLOValue
41
RLMDSentiment
62
RLMDRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs RLMD
ALLO is the first peer returned for this comparison set.